Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

Show other versions (1)

Background Non-alcoholic fatty liver disease has reached epidemic proportions in type 2 diabetes (T2D). Glucagon-like peptide-1 analogues are licensed in T2D, yet little data exist on efficacy and safety in liver injury. Aim To assess the safety and efficacy of 26-week liraglutide on liver parameter...

Full description

Bibliographic Details
Main Authors:	Armstrong, M, Houlihan, D, Rowe, I, Clausen, W, Elbrønd, B, Gough, S, Tomlinson, J, Newsome, P
Format:	Journal article
Language:	English
Published:	2013

Similar Items

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
by: Armstrong, M, et al.
Published: (2013)

Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme
by: Armstrong, M, et al.
Published: (2013)

High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program
by: Armstrong, M, et al.
Published: (2010)

EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL
by: Armstrong, M, et al.
Published: (2010)

High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program
by: Armstrong, M, et al.
Published: (2010)

Liraglutide for patients with non-alcoholic steatohepatitis.
by: Dale, A, et al.
Published: (2016)

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
by: Armstrong, M, et al.
Published: (2013)

The role of liver biopsy for asymptomatic liver enzyme elevation
by: Le Mire, M, et al.
Published: (2005)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
by: Nauck, M, et al.
Published: (2009)

Liraglutide: from clinical trials to clinical practice.
by: Gough, S
Published: (2012)

Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome.
by: Fitzpatrick, K, et al.
Published: (2014)

Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study
by: Stephens, J, et al.
Published: (2014)

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
by: Hermansen, K, et al.
Published: (2010)

Current therapeutic strategies in non-alcoholic fatty liver disease.
by: Dowman, J, et al.
Published: (2011)

Reductions in HbA(1c) and the incidence of hypoglycaemic episodes are not affected by renal impairment in patients with type 2 diabetes treated with liraglutide
by: Gough, S, et al.
Published: (2011)

Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases.
by: Martins, E, et al.
Published: (1996)

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis
by: Kotecha, D, et al.
Published: (2014)

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.
by: Kotecha, D, et al.
Published: (2014)

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial
by: Armstrong, M, et al.
Published: (2013)

Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis.
by: Newsome, P, et al.
Published: (2012)

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis
by: Armstrong, M, et al.
Published: (2014)

Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis.
by: Armstrong, M, et al.
Published: (2014)

Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstrom syndrome.
by: Gathercole, L, et al.
Published: (2016)

Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data
by: Frid, A, et al.
Published: (2009)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
by: Nauck, M, et al.
Published: (2009)

Pathogenesis of non-alcoholic fatty liver disease.
by: Dowman, J, et al.
Published: (2010)

The diagnosis of non-alcoholic fatty liver disease: authors' reply
by: Dowman, J, et al.
Published: (2012)

Subcutaneous adipose tissue insulin resistance and lipolysis in patients with nonalcoholic steatohepatitis
by: Armstrong, M, et al.
Published: (2013)

Liraglutide in Children and Adolescents with Type 2 Diabetes
by: Tamborlane, William V., et al.
Published: (2019)

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
by: Nauck, M, et al.
Published: (2013)

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
by: Nauck, M, et al.
Published: (2013)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
by: Robinson, L, et al.
Published: (2013)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
by: Robinson, L, et al.
Published: (2013)

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis
by: Kotecha, D, et al.
Published: (2016)

Safety and efficacy of primaquine in patients with Plasmodium vivax malaria from South Asia: a systematic review and individual patient data meta-analysis
by: Verma, R, et al.
Published: (2023)

Individual patient data meta-analysis in cancer.
by: Clarke, M, et al.
Published: (1998)

What is an individual patient data meta-analysis?
by: Cipriani, A, et al.
Published: (2007)

Efficacy of vaccine protection against COVID-19 virus infection in patients with chronic liver diseases
by: Cheung, Carmen Ka Man, et al.
Published: (2024)

Survey on knowledge and herbal intake among patients with elevated level of hepatic transaminase enzymes in medical ward HUSM
by: Khairunnisa, Abas
Published: (2009)

Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
by: Zinman, B, et al.
Published: (2011)